Media coverage about American Renal Associates Holdings (NYSE:ARA) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. American Renal Associates Holdings earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.5853462567052 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s analysis:
- American Renal Associates : Kidney Fund Prepares for Hurricane Irma Disaster Relief and Helps Hundreds of Dialysis Patients Affected by Harvey (4-traders.com)
- ETFs with exposure to American Renal Associates Holdings, Inc. : September 9, 2017 (finance.yahoo.com)
- American Renal Associates Holdings, Inc. :ARA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 7, 2017 (finance.yahoo.com)
- American Renal Associates Holdings Inc (ARA) Expected to Post Quarterly Sales of $196.15 Million (americanbankingnews.com)
Separately, Zacks Investment Research raised American Renal Associates Holdings from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $22.33.
American Renal Associates Holdings (ARA) traded up 0.719% during mid-day trading on Tuesday, hitting $14.715. The stock had a trading volume of 113,159 shares. American Renal Associates Holdings has a 12-month low of $13.48 and a 12-month high of $25.42. The firm’s market cap is $460.36 million. The company has a 50-day moving average of $15.21 and a 200-day moving average of $17.29.
American Renal Associates Holdings (NYSE:ARA) last issued its earnings results on Tuesday, August 8th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.04. American Renal Associates Holdings had a negative net margin of 1.54% and a positive return on equity of 18.25%. The firm had revenue of $185.99 million for the quarter, compared to analysts’ expectations of $188.23 million. The company’s quarterly revenue was up .2% compared to the same quarter last year. Analysts expect that American Renal Associates Holdings will post $0.54 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “American Renal Associates Holdings (ARA) Getting Somewhat Favorable Media Coverage, Report Shows” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/09/12/american-renal-associates-holdings-ara-getting-somewhat-favorable-media-coverage-report-shows.html.
About American Renal Associates Holdings
American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.
Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.